BTIG analyst Justin Zelin maintained a Buy rating on BELLUS Health (BLU – Research Report) on February 23 and set a price target of $18.00. The company's shares closed last Wednesday at $6.06. According to TipRanks.com, Zelin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.5% and a 28.1% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, Viking Therapeutics, and Legend Biotech. Currently, the analyst consensus on BELLUS Health is a Strong Buy with an average price target of $16.63, which is a 185.2% upside from current levels.
https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-bellus-health-blu?utm_source=advfn.com&utm_medium=referral
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Mar 2023 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Apr 2022 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.